A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. - Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B (Melanoma research, 2022)